Teva Pharmaceutical Industries Limited (TEVA) Receives ‘Analyst’ Rating

Teva Pharmaceutical Industries Limited (TEVA) : 17 analysts are covering Teva Pharmaceutical Industries Limited (TEVA) and their average rating on the stock is 1.56, which is read as a Buy. 11 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Teva Pharmaceutical Industries Limited (TEVA) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 4 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Teva Pharmaceutical Industries Limited (TEVA) : The consensus price target for Teva Pharmaceutical Industries Limited (TEVA) is $71.68 for the short term with a standard deviation of $10.67. The most optimist securities analyst among the 16 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $57.


Also, Equity analysts at the Brokerage firm Oppenheimer upgrades its rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA). The rating major has initiated the coverage with outperform rating on the shares. Earlier, the shares were rated a Perform by the brokerage firm. The rating by the firm was issued on September 2, 2016.

Teva Pharmaceutical Industries Limited (NYSE:TEVA): The stock opened in the green at $52.02 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $52.28 and a low of $51.4 for the day. The stock did not find buyers even at the lows and closed at $51.9 recording a loss of -0.10%. 3,568,438 shares exchanged hands during the trading day. The stock had closed at $51.95 in the previous days trading.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Companys generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams, and Specialty medicines, which delivers solutions to patients and providers via medicines, devices and services. Its Central Nervous System (CNS) portfolio includes Copaxone, Azilect and Nuvigil. Its main respiratory medicines include ProAir hydrofluoroalkane, QVAR and Duoresp Spiromax. Its oncology portfolio includes Treanda, Trisenox, Granix Synribo, Lonquex, Tevagrastim/Ratiograstim, Myocet, Trisenox and Eporatio. Its womens health portfolio includes ParaGard, Plan B One-Step OTC/Rx (levonorgestrel) and Zoely.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.